"Theresa has exceptional knowledge and expertise. She is creative and a highly effective negotiator."
— Health Care Client, Chambers USA 2025
Theresa is a nationally recognized health care and pharmaceutical supply chain attorney who advises clients on PBM strategy, drug pricing, and the regulatory and transactional issues shaping the pharmaceutical industry. With more than 25 years of experience, she combines sophisticated legal judgment with deep industry insight to help clients navigate complex commercial, regulatory, and policy environments.
Theresa has extensive experience structuring, drafting, and negotiating transactions across the pharmaceutical supply chain, including PBM service agreements, retail, mail, and specialty pharmacy arrangements, pharmaceutical purchase and distribution agreements, GPO arrangements, and rebate and value-based contracting models. She regularly advises clients on reimbursement structures, drug pricing strategy, and compliance with federal and state fraud and abuse laws.
Her practice spans health care transactions and investment matters, where she represents clients in mergers, private equity and venture capital investments, and strategic collaborations. Theresa supports regulatory diligence, licensing, change-of-ownership filings, and risk assessment across complex health care and pharmaceutical supply chain deals.
Theresa counsels PBMs, health plans, pharmacies, and distribution stakeholders on operational, regulatory, and compliance matters across commercial, Medicare Advantage, Part D, and multistate health care markets. She helps clients evaluate structural design considerations, policy developments, and business opportunities associated with innovation in drug delivery, reimbursement, and emerging service models.
Recognized as an industry thought leader, Theresa frequently communicates timely updates on regulatory, policy, and market developments affecting clients in the pharmaceutical supply chain. She is a regular author and speaker on health care regulatory and PBM-related issues.
Theresa is a member of the firm's Policy Committee.
Experience
- Represented LucyRx, a Summit Partners portfolio company and next-generation pharmacy benefit manager, in connection with multiple strategic growth initiatives, including its strategic combination with Abarca Health, acquisitions of CerpassRx, Integrated Prescription Management (IPM), and HealthSmart’s PBM business, and a strategic PBM affiliation with CitizensRx.
- Represented Cigna as health regulatory counsel in its acquisition of Express Scripts.
- Represented Catamaran (f/k/a CatalystRx) in the structuring and negotiation of its PBM services arrangement with CIGNA.
- Represented national worker’s compensation PBM in connection with multiple workers' compensation PBM acquisitions.
- Represented a national specialty pharmacy provider in connection with an internal compliance audit and investigation and response to government investigation.
- Advised national pharmacy chain in multiple specialty pharmacy and long-term care pharmacy acquisitions.
- Represented SingleCare, a discount medical and pharmacy card operator (DMPO), in its contracting with pharmacies, providers, and other vendors.
- Served as regulatory counsel to a consortium of investors led by TPG Capital and Welsh, Carson, Anderson & Stowe in their $4.1 billion acquisition of Kindred Healthcare, Inc. (NYSE: KND). The transaction was recognized by The Deal as the 2018 Private Equity Deal of the Year.
- Advised a global health care company on a variety of issues in connection with its acquisition of several health plans and provider groups, including health care regulatory due diligence, health care regulatory advice regarding transaction structure and strategy, and preparation of regulatory notices and other filings.
- Advised national pharmacy chain in connection with government agency arrangement to provide accessible COVID-19 testing.
viewpoints
A Pivotal Week for Pharmaceutical Policy: Trump Administration Advances Tariff and Drug Pricing Initiatives
October 7, 2025 | Blog | By Theresa Carnegie, Stephnie John, Hassan Shaikh, Attiya S. Khan, Grace Callander, Sneha Shenoy
The first week of October 2025 marked a significant shift in U.S. drug pricing policy as the Trump administration unveiled a series of sweeping actions to deliver on his promise to lower drug prices. From President Trump’s announcement of a 100% tariff on imported branded drugs to the Trump administration’s landmark pricing deal with Pfizer and the rollout of the TrumpRx.gov direct-to-consumer (DTC) platform, last week marked an escalation in the White House’s efforts to drive down prescription drug costs and bring pharmaceutical manufacturing back to U.S. soil. Below, we provide an overview of the Trump administration’s new policies and the stakeholder responses already reshaping the broader pharmaceutical landscape.
Mintz IRA Update — Still Undefeated: Government Notches Three More Victories in Negotiation Program Lawsuits
September 15, 2025 | Article | By Theresa Carnegie, Mitchell Clough, Xavier Hardy, Hassan Shaikh
Federal courts continue to uphold the Medicare Drug Price Negotiation Program, with multiple rulings emphasizing the voluntary nature of manufacturer participation. Key legal challenges from AstraZeneca, Boehringer Ingelheim, PhRMA, and others face setbacks as the government remains undefeated.
Mintz IRA Update — PhRMA’s 2025 Policy Agenda and the Industry’s Crossroads with the IRA and Drug Pricing Reform
September 15, 2025 | Article | By Theresa Carnegie, Hassan Shaikh
PhRMA’s 2025 agenda pushes back on drug pricing reforms, calling for innovation-friendly policies, 340B reform, and PBM accountability.
Mintz IRA Update — Disrupting the Pharmaceutical Supply Chain: The Era of the DTC Model
September 15, 2025 | Article | By Theresa Carnegie, Stephnie John
While the pharmaceutical industry has reacted negatively to President Trump’s May 12 “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” Executive Order (Executive Order), manufacturers appear to be leveraging one of Trump’s directives in the Executive Order, accelerating the industry’s shift toward a new model of drug delivery: direct-to-consumer (DTC) programs.
Mintz IRA Update — Under Pressure: The Trump Administration’s Drug Pricing Executive Orders
September 15, 2025 | Article | By Theresa Carnegie, Xavier Hardy, Hassan Shaikh, Abdie Santiago
President Trump issues executive orders and letters to curb drug costs, promote MFN pricing, and reform Medicare’s Negotiation Program.
Mintz IRA Update — Medicare Part B Physician Fee Schedule Guidance and Its Potential Implications for Medicare Part D
September 15, 2025 | Article | By Theresa Carnegie, Tara E. Dwyer, Rachel Yount, Hassan Shaikh
The CY 2026 Physician Fee Schedule Proposed Rule (PFS Proposed Rule) introduces significant changes to how drug manufacturers must treat Bona Fide Service Fees (BFSFs) when calculating Average Sales Price (ASP) for Medicare Part B drugs.
Mintz IRA Update — The Uncertain State of Affairs for GLP-1s
September 15, 2025 | Article | By Theresa Carnegie, Hassan Shaikh, Samantha Hawkins
GLP-1 receptor agonists (GLP-1s) such as semaglutide, and dual agonists like tirzepatide, are transforming obesity treatment and reshaping the US health care landscape.
Trump Sends Letters to Manufacturers Regarding Most-Favored-Nation Executive Order Requirements
August 8, 2025 | Blog | By Theresa Carnegie, Bridgette Keller, Sophia Temis
In follow-up to the May 12th “Delivering Most Favored Nation Prescription Drug Pricing to American Patients” Executive Order, President Trump issued letters to seventeen manufacturers (Letters), reiterating the mandate for manufacturers to provide the United States with most-favored-nation pricing for drugs.
As we previously reported, the Executive Order gave manufacturers 180 days to negotiate most-favored-nation drug pricing terms with the Department of Health and Human Services (HHS) before the Attorney General and the Chairman of the Federal Trade Commission (FTC) can bring enforcement action against manufacturers for anti-competitive practices. The Executive Order also warned manufacturers that the HHS Secretary and heads of other agencies would consider alternative measures to compel manufacturers to modify drug prices if “significant progress toward most-favored-nation pricing for American patients [was] not delivered.” These measures include, but are not limited to, issuing rulemaking to impose most-favored-nation pricing, certifying to Congress that importation is a viable drug cost-reduction strategy, and modifying or revoking existing drug approvals.
Federal Court Blocks Arkansas PBM Ownership Law, Citing Constitutional Violations
August 6, 2025 | Blog | By Theresa Carnegie, Samantha Hawkins
In a significant legal development, a federal judge has temporarily blocked Arkansas from enforcing Act 624. Act 624 prohibits pharmacy benefit managers (PBMs) from owning or operating pharmacies in the state, effectively forcing vertically integrated companies to divest or shut down their Arkansas pharmacy operations. However, on July 28, 2025, U.S. District Judge Brian Miller granted a preliminary injunction to several major PBMs and affiliated entities, halting the law’s implementation pending final resolution of the case.
CMS Proposes New Standards for Bona Fide Service Fees in Average Sales Price Calculations: What Plans, PBMs, and Other Recipients of BFSFs Need to Know
July 30, 2025 | Blog | By Theresa Carnegie, Tara E. Dwyer, Rachel Yount
The CY 2026 Physician Fee Schedule Proposed Rule (PFS Proposed Rule) introduces significant changes to how drug manufacturers must treat Bona Fide Service Fees (BFSFs) when calculating Average Sales Price (ASP) for Medicare Part B drugs. While the rule is directed at manufacturers, it has important implications for plans, pharmacy benefit managers (PBMs), group purchasing organizations (GPOs), and other entities that receive BFSFs, particularly if the Centers for Medicare & Medicaid (CMS) proposes similar changes to Part D.
News & Press
8 Takeaways from the MHE and Drug Topics Post-Midterms Webinar
November 7, 2026|
CVS’ Drugstores, a Long Familiar Brand, Have Had a Big Problem for Years
November 6, 2026|
FAQ: State PBM Reform in 2026—What's New Since Spring
September 30, 2026|
What to Know About State-Level PBM Reform
June 23, 2026|
Latest PBM Settlement to Reverberate Through Health Plans
April 22, 2026|
PBMs Enter New Era of Legal Scrutiny
February 10, 2026|
Legal Risks Complicate Drugmakers' TrumpRx Participation
February 3, 2026|
Transparency, New Players Shake up PBM Landscape
September 11, 2025|
States Become More Aggressive with PBM Reform
May 30, 2025|
Despite Vaccine Spotlight, RFK Jr. A Health Policy 'Unknown'
November 15, 2024|
HHS Pushes Back on Accumulator Ruling, Prompting Wait-and-See Situation
December 21, 2023|
4 Pharma Industry Arguments Against CMS Drug Pricing Plan
September 29, 2023|
Medicare’s 10-Drug List: The Industry Reacts
August 30, 2023|
Five Mintz Attorneys Named 2020 BTI Client Service All-Stars
December 11, 2020|
Trump Unveils Disputed, Long-Shot Drug Rules Upending System
November 23, 2020|
Mintz Advising Consortium in $4+ Billion Acquisition of Kindred Healthcare
December 21, 2017|
podcasts
Health Law Diagnosed – New Year's Gratitude
February 3, 2025 | Podcast | By Bridgette Keller, Alison H. Peters, Samantha Kingsbury, Theresa Carnegie, Joanne Hawana , Abdie Santiago, Stephnie John, Pamela Polevoy, Karen Lovitch , Jean D. Mancheno, Deborah Daccord, Rachel A. Alexander, Jane Haviland, David Gilboa, Kathryn Edgerton, Hassan Shaikh, Madison Castle, Laurence Freedman, Priyanka Amirneni, Samantha Hawkins, Tara E. Dwyer, Rachel Yount, Sophia Temis, Xavier Hardy
Host Of Counsel Bridgette Keller invites the Mintz Health Law team to reflect on what they’re grateful for as they prepare for the year ahead. Hear from a dynamic group of Members, Of Counsel, and Associates as they share their perspectives on what’s coming up over the horizon.
Mintz Health Law: What We Are Grateful For
January 11, 2023 | Podcast | By Bridgette Keller
Bridgette Keller speaks with the Mintz Health Law team about what they are grateful for as they look back on a year of client service, mentorship, and working together as a team.
Events & Speaking
Regulatory Complexity — Contracts, Transparency, and State-by-State Fragmentation
PBM Contracting Summit 2026
Chicago, IL
AHLA Health Plan and Managed Care Law Institute
Drug Pricing in 2026: Trump Rx and Other Developments
Virtual
New Landmark Pharmacy Benefit Managers Reform: Increased Transparency, Reporting, Federal Oversight, Enforcement
BARBRI Webinar
Virtual
Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance Issues
Strafford Webinar
Virtual
Examining the Impact of COVID-19 on Pharmacy Benefits and the Pharmaceutical Supply Chain
American Health Law Association Annual Meeting
Online Event
4th Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
3rd Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
3rd Annual Mintz /ML Strategies Pharmacy & Pharmaceutical Industry Summit
Mintz and ML Strategies
Boston, MA
Pharmacy Benefits and Pharmaceuticals: State of the Industry Update
AHLA
Marriott Chicago Downtown, Magnificent Mile, Chicago, IL
4th Annual Pharmacy Benefit Oversight & Compliance Conference
CBI
16770 North Perimeter Drive Scottsdale, AZ
Recognition & Awards
BTI Consulting Group: Client Service All-Star (2020)
Chambers USA: District of Columbia (Up and Coming) – Healthcare (2014, 2015); District of Columbia – Healthcare (2023 - 2026)
Legal 500 United States: Recognized for Healthcare: Service Providers (2024)
Nightingale’s Healthcare News: Outstanding Young Healthcare Lawyers (2005)
Phi Beta Kappa


